PD-L1 Expression and Immune Response in Squamous Cervical Lesion and Squamous Cell Carcinoma Cervix

  • Riadi Department of Anatomical Pathology, Faculty of Medicine, Hasanuddin University, Makassar 90245, Indonesia).
  • Rina Masadah Department of Anatomical Pathology, Faculty of Medicine, Hasanuddin University, Makassar 90245, Indonesia).
  • Syarifuddin Wahid Department of Anatomical Pathology, Faculty of Medicine, Hasanuddin University, Makassar 90245, Indonesia).
  • Berti Nelwan Department of Anatomical Pathology, Faculty of Medicine, Hasanuddin University, Makassar 90245, Indonesia).
  • Upik A. Miskad Department of Anatomical Pathology, Faculty of Medicine, Hasanuddin University, Makassar 90245, Indonesia).
  • Andi Alfian Zainuddin Department of Anatomical Pathology, Faculty of Medicine, Hasanuddin University, Makassar 90245, Indonesia).
Keywords: PD-L1, TILs, cervical intraepithelial lesion, cervical squamous cell carcinoma

Abstract

Aim : To explore the possibility of using anti-PD-L1 immunotherapy in low-grade intraepithelial lesion (LSIL), high-grade intraepithelial lesion (HSIL), and squamous cell carcinoma (SCC) of the cervix. Material and methods: PD-L1 expression was analyzed by an immunohistochemical technique using an anti-PD-L1 antibody. Tumour infiltrating lymphocytes (TILs) were analyzed by comparing the area occupied by lymphocytes with the stromal area between tumors. Result: there was a statistical difference between PD-L1 expression and TILs (p < 0.001). PD-L1 expression appeared higher in cervical intraepithelial lesion than squamous cell carcinoma, but there was no statistical difference (p = 0.781). Conclusion: It is possible to use anti-PD-L1 in cervical intraepithelial squamous lesions and cervical squamous cell carcinoma.

References

J. Ferlay et al., “Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods,” International Journal of Cancer, vol. 144, no. 8, pp. 1941–1953, Apr. 2019, doi: https://doi.org/10.1002/ijc.31937.

L. Guo, Y. Lin, and H. Fai Kwok, “The function and regulation of PD-L1 in immunotherapy,” ADMET and DMPK, vol. 5, no. 3, pp. 159–172, 2017.

W. Lin, M. Chen, L. Hong, H. Zhao, and Q. Chen, “Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC,” Frontiers in Oncology, vol. 8, Aug. 2018, doi: 10.3389/fonc.2018.00532.

N. Yaghoubi, A. Soltani, K. Ghazvini, S. M. Hassanian, and S. I. Hashemy, “PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer,” Biomedicine and Pharmacotherapy, vol. 110, no. September 2018, pp. 312–318, 2019, doi: 10.1016/j.biopha.2018.11.105.

F. C. Santini and M. D. Hellmann, “PD-1/PD-L1 Axis in Lung Cancer.,” Cancer J, vol. 24, no. 1, pp. 15–19, 2018.

A. D. Santin et al., “Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix,” Gynecol Oncol, vol. 89, no. 2, pp. 271–280, 2003.

C. Liu et al., “Increased expression of PD-L1 by the human papillomavirus 16 E7 oncoprotein inhibits anticancer immunity,” Molecular Medicine Reports, vol. 15, no. 3, pp. 1063–1070, Aug. 2017, doi: 10.3892/mmr.2017.6102.

L. Mezache, B. Paniccia, A. Nyinawabera, and G. J. Nuovo, “Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers,” Modern Pathology, vol. 28, no. 12, p. 1594, 2015.

W. Yang, Y. Song, Y.-L. Lu, J.-Z. Sun, and H.-W. Wang, “Increased expression of programmed death (PD)‐1 and its ligand PD‐L1 correlates with impaired cell‐mediated immunity in high‐risk human papillomavirus‐related cervical intraepithelial neoplasia,” Immunology, vol. 139, no. 4, pp. 513–522, 2013.

K. Tainio et al., “Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis,” BMJ, vol. 360, pp. k499–k499, Feb. 2018, doi: 10.1136/bmj.k499.

I. Nicolás et al., “HPV-negative tumors of the uterine cervix.,” Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, vol. 32, no. 8, pp. 1189–1196, Jul. 2019, doi: 10.1038/s41379-019-0249-1.

Y. Dong, Q. Sun, and X. Zhang, “PD-1 and its ligands are important immune checkpoints in cancer,” Oncotarget, vol. 8, no. 2, p. 2171, 2017.

R. Salgado et al., “The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014,” Annals of oncology, vol. 26, no. 2, pp. 259–271, 2015.

W. Yang, Y. Song, Y.-L. Lu, J.-Z. Sun, and H.-W. Wang, “Increased expression of programmed death (PD)‐1 and its ligand PD‐L1 correlates with impaired cell‐mediated immunity in high‐risk human papillomavirus‐related cervical intraepithelial neoplasia,” Immunology, vol. 139, no. 4, pp. 513–522, 2013.

L. Mezache, B. Paniccia, A. Nyinawabera, and G. J. Nuovo, “Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers,” Modern Pathology, vol. 28, no. 12, p. 1594, 2015, [Online]. Available: http://files/150/Mezache et al. - 2015 - Enhanced expression of PD L1 in cervical intraepit.pdf

H. A. Katki et al., “Five-year risks of CIN 3+ and cervical cancer among women with HPV-positive and HPV-negative high-grade Pap results.,” J Low Genit Tract Dis, vol. 17, no. 5 Suppl 1, pp. S50-5, Apr. 2013, doi: 10.1097/LGT.0b013e3182854282.

X. Gu et al., “Elevated PD-L1 expression predicts poor survival outcomes in patients with cervical cancer,” Cancer Cell International, vol. 19, no. 1, p. 146, Mar. 2019, doi: 10.1186/s12935-019-0861-7.

Y. Meng et al., “PD-L1 Expression correlates with tumor infiltrating lymphocytes and response to neoadjuvant chemotherapy in cervical cancer,” J Cancer, vol. 9, no. 16, p. 2938, 2018.

S. Stevanović et al., “Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells,” Journal of Clinical Oncology, vol. 33, no. 14, pp. 1543–1550, 2015, doi: 10.1200/JCO.2014.58.9093.

Published
2022-05-28
How to Cite
Riadi, Rina Masadah, Syarifuddin Wahid, Berti Nelwan, Upik A. Miskad, & Andi Alfian Zainuddin. (2022). PD-L1 Expression and Immune Response in Squamous Cervical Lesion and Squamous Cell Carcinoma Cervix. International Journal of Sciences: Basic and Applied Research (IJSBAR), 62(2), 182-188. Retrieved from https://gssrr.org/index.php/JournalOfBasicAndApplied/article/view/14091
Section
Articles